<DOC>
	<DOC>NCT00282386</DOC>
	<brief_summary>This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>Eligible patients must have undergone a complete colonoscopy within 12 weeks of study entry with removal of all polyps; at least one polyp must have been confirmed a large bowel precancerous polyp (adenoma) by the study pathologist. History with a specific hereditary large bowel polyp syndrome History of a large bowel adenoma before age 35 Small or large bowel resection or history of inflammatory bowel disease History of cancer within the five years before enrollment Expected need for chronic NSAID therapy Positive test result for stool occult blood Uncontrolled hypertension, stroke or temporary mini stroke (TIA) within the past 2 years, angina or congestive heart failure with symptoms that occur at rest or with minimal activity History of myocardial infarction (heart attack), coronary angioplasty, or coronary artery bypass grafting within the past 1 year Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>